UNSPSC 51112605: Galamustine

This classification denotes a nitrogen mustard compound with the molecular formula C10H19Cl2NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P771FDQ1WJ, chemically known as d-galactopyranose, 6-(bis(2-chloroethyl)amino)-6-deoxy- but more generally known as galamustine, which bears US NIH Compound Identifier 65891. European Medicines Agency schedules Galamustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07869MIG.

UNSPSC 51112605 Galamustine, a Commodity code, addresses pharmaceutical products procured through state health and human services agencies. The Texas Health and Human Services Commission's April 2026 Request for Information regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program illustrates the work being solicited under this code: state procurement offices are gathering market intelligence on vendors' capacity to establish direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers, bypassing traditional pharmacy benefit managers and group purchasing organizations, with an emphasis on negotiated net pricing models and outcomes-based contracting structures. The code captures individual pharmaceutical commodities purchased by state health agencies as part of broader pharmacy benefit management strategy; in this case, the RFI seeks vendor experience with direct contracting for self-insured employers and government health plans, fulfillment strategies, and participation in multi-jurisdictional government employee and retiree purchasing vehicles.

State health and human services commissions represent the primary issuing body under this code. Geographic activity is concentrated in Texas based on the recent RFI. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor responses on the same date, marking an early-stage market intelligence phase designed to inform future formal competitive solicitation strategy for pharmaceutical direct-to-manufacturer procurement before the state issues a formal RFP with established financial parameters and response timelines.